Format:
24
ISSN:
2072-6694
Content:
Head and neck squamous cell carcinoma (HNSCC) is the sixth most commonly diagnosed cancer worldwide. Despite advances in the treatment management, locally advanced disease has a poor prognosis, with a 5-year survival rate of approximately 50%. The growth of HNSCC is maintained by a population of cancer stem cells (CSCs) which possess unlimited self-renewal potential and induce tumor regrowth if not completely eliminated by therapy. The population of CSCs is not only a promising target for tumor treatment, but also an important biomarker to identify the patients at risk for therapeutic failure and disease progression. This review aims to provide an overview of the recent pre-clinical and clinical studies on the biology and potential therapeutic implications of HNSCC stem cells.
Note:
Gesehen am 20.08.2019
In:
Cancers, Basel : MDPI, 2009, 11(2019,5) Artikel-Nummer 616, 24 Seiten, 2072-6694
In:
volume:11
In:
year:2019
In:
number:5
In:
extent:24
Language:
English
DOI:
10.3390/cancers11050616
